The obscure advisory committees at the heart of the U.S. drug pricing debate

by reuter.com
http://bit.ly/pnED7n
Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries.

Read more

Share on Facebook Share on Twitter Share on Google Plus

About New

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.